A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD

Sickle Cell Disease Clinical Trial

Official title: A Phase II Stratified Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With Sickle Cell Disease With no Available Sibling Donor

Status Recruiting

Clinical Trial Summary

HSCT is currently the only curative option for SCD but less than 20% of SCD patients have a MD donor available. So far, all curative approaches beyond a MSD HSCT at young age are non-satisfactory. With the lack of a suitable donor for the vast majority of patients, the major question of this trial is, if a haploidentical αß/CD19+ T-cell depleted HSCT can be a valid alternative to a MSD HSCT. The main challenge in non-malignant diseases is to offer a safe and GvHD-free HSCT without rejection.

Clinical Trial Description

Can an α/ß depleted T-Haplo-HSCT with regard to disease free survival, adverse events and safety be considered equivalent to a matched sibling donor transplantation (MSD), in order to offer cure for the majority of patients with sickle cell disease.

The main questions of this trial are:

• Safety of a α/ß T-depleted haploidentical HSCT

• Incidence of acute and chronic GvHD

• Rate of rejection

• Immune reconstitution

• Fertility It is expected that the use of TCRαβ+ and CD19+ depleted haploidentical cell grafts in combination with the less aggressive and well tolerated conditioning regimen needed for patient preparation will be associated with a low risk of grade II-IV aGVHD and no extensive cGvHD, no graft failure and increase speed, spectrum and functionality of immune system reconstitution. This is supposed to reduce the incidence of severe infections leading to lower rates of transplantation related mortality (TRM). ;

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• HbS Disease
• Hemoglobin S Disease
• Sickle Cell Anemia
• Sickle Cell Disease
• Sickle Cell Disorders
• Sickle Cell Trait
• Sickling Disorder Due to Hemoglobin S

• NCT number: NCT04201210
• Study type: Interventional
• Source: University of Regensburg
• Contact: Selim Corbacioglu, MD
• Phone: +49 (0)941 944-2101
• Email: Haplo.SCD@ukr.de
• Status: Recruiting
• Phase: Phase 2
• Start date: June 30, 2021
• Completion date: March 31, 2030